855 Spam-Free Article(s) Found
||Teva Pharmaceutical Industries Limited
Aug 25, 2015 - Acorda (ACOR) received encouraging news with the patent review board refusing to review two patents related to Ampyra.
Aug 25, 2015 - The changes disclosed last week to Teva’s (NYSE:TEVA) phase III trial with the Mesoblast-licensed CEP-41750/rexlemestrocel-L stem cell therapy in chronic heart failure are ostensibly designed t
Aug 25, 2015 - Despite Capaxone worries, Teva is growing organically, and its fundamental strengths continue to be evident in quarterly reports.
Aug 24, 2015 - Novartis (NVS) inked a deal with GlaxoSmithKline to acquire all remaining rights to Arzerra for up to $1 billion plus royalties.
Jul 27, 2015 - Questions about the sustainability of Chinese government funds' ability to stabilize the market cause a pullback in market support. As a result, the Shanghai index dropped 8.5 percent and the Shenzhen was down 7 percent.